STERIS - Q2 2024

Transcript

Operator (participant)

Good morning, everyone, and welcome to the STERIS plc Fiscal Q2 2024 Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the Star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star and then one on your touch-tone telephones. To withdraw your question, you may press Star and two. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Julie Winter, Vice President of Investor Relations. Ma'am, please go ahead.

Julie Winter (VP of Investor Relations and Corporate Communications)

Thank you, Jamie, and good morning, everyone. As usual, speaking on today's call will be Mike Tokich, our Senior Vice President and CFO, and Dan Carestio, our President and CEO. I do have a few words of caution before we open for comments. This webcast contains time-sensitive information that is accurate only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Some of the statements made during this review are or may be considered forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS's securities filings. The company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments.

STERIS's SEC filings are available through the company and on our website. In addition, on today's call, non-GAAP financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow, will be used. Additional information regarding these measures, including definitions, is available in our release, as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the board of directors in their financial analysis and operational decision making. With those cautions, I will hand the call over to Mike.

Michael Tokich (SVP and CFO)

Thank you, Julie, and good morning, everyone. It's once again my pleasure to be with you this morning to review the highlights of our Q2 performance. For the quarter, constant currency organic revenue increased 8%, driven by volume as well as 330 basis points of price. Gross margin for the quarter decreased 50 basis points compared with the prior year to 44.3%. Favorable price was more than offset by lower productivity and continued material and labor inflation. EBIT margin decreased 130 basis points to 22.5% of revenue compared with the Q2 last year, which reflects the decline in gross margin, as well as the anticipated increase in year-over-year incentive compensation expense. The adjusted effective tax rate in the quarter was 23.7%.

Net income in the quarter was $202.2 million, and adjusted earnings were $2.03 per diluted share. Capital expenditures for the first half of fiscal 2024 totaled $149.9 million, while depreciation and amortization totaled $290.2 million. We are adjusting our capital spending outlook for fiscal 2024, down from $375 million to $310 million. This change reflects the timing of projects for our AST business. This change will allow us to offset higher than planned inventory levels, keeping free cash flow outlook for fiscal 2024 at approximately $685 million. Debt increased to $3.4 billion in the Q2, reflecting borrowings to fund the acquisition of the BD assets.

Total debt to EBITDA at quarter end was approximately 2.3 times gross leverage. Free cash flow for the first half of fiscal 2024 was $284.7 million, as we benefited from lower capital spending and a decline in cash used for tax and compensation-related payments. Inventory remains elevated as we continue to focus on reducing lead times and meeting customer demand. With that, I'll turn the call over to Dan for his remarks.

Dan Carestio (President and CEO)

Thanks, Mike, and good morning, everyone. Thank you for making the time to join us to hear more about our Q2 performance and our outlook for the rest of the fiscal year. As you heard from Mike, our Q2 continued the momentum we have experienced in our healthcare segment for the past few quarters. Overall, we are very pleased with our performance in the healthcare segment and is anticipated to outperform our original expectations for the fiscal year, offsetting the macro challenges impacting demand in our other segments. Looking at our segments, healthcare constant currency organic revenue grew 14% in the quarter. We experienced double-digit growth across capital equipment, consumables, and service again this quarter. This is driven primarily by procedure volume rebound in the U.S., as well as price and market share gains.

As anticipated, our backlog has reduced as we are able to ship at a faster pace than new orders are coming in as we get back to normal lead times for our customers. During the first half, we saw a strength in replacement orders, representing 65% of our total orders in healthcare. We are increasingly confident in our expectations of a strong year for our healthcare segment. Growth will, however, decelerate in the second half as we face very challenging comparisons in the Q4. Turning to AST, constant currency organic revenue declined 1%. While our services business grew 5%, our capital equipment business declined due to the timing of large shipments. In addition, our performance in the quarter continued to be impacted by two short-term situations: inventory destocking in the medtech space and the year-over-year market decline of the bioprocessing customer demand.

We do see very positive signs of recovery in the medtech demand. We saw good growth in the U.S. during the quarter, reflecting the improving procedure environment and the burn down of customer inventory. We continue to see weakness, however, in the European markets, where procedure recovery is taking a bit longer to take hold. From a bioprocessing perspective, as we have said, FY 2024 represents a bit of a reset, and we do not anticipate returning to year-over-year growth in bioprocessing in fiscal 2024. As we head into the second half, our comps ease as it was the Q3 of fiscal 2023 when we first witnessed declines in bioprocessing. Based on these factors, our outlook continues to reflect very strong growth in the second half of the fiscal year for our AST segment as compared to the first half.

Life Sciences revenue grew 5% in the quarter on a constant currency organic basis, as the delayed capital shipments from the first quarter were recognized, contributing to 18% growth in capital equipment. Consumables grew 4%, and service was flat. As you are hearing from many others in the space, the short-term demand remains a bit murky. We continue, however, to be very optimistic about the long-term trends driving demand for aseptic manufacturing and biopharma. Our Dental segment, Q2 revenue declined 6% on a constant currency organic basis, as revenue was limited by customer destocking of inventory, in particular for infection control products. Despite these challenges, we are impressed with the ability of the business to sequentially improve margins, delivering EBIT margins above total company in the quarter. All in, we are pleased with the first half of the fiscal year.

U.S. procedure trends continue to shift in a positive direction, supply chain challenges have largely abated, and our ability to execute and ship capital products to our customer delivery times has greatly improved. That said, there are still pockets of uncertainty which remain outside of our healthcare segment. We are maintaining our expectations of 6%-7% constant currency organic revenue growth for fiscal 2024, as we expect a very strong Q3, followed by a very tough Q4 comparisons, which will limit our total growth in the second half. In addition, from an earnings perspective, we now have an additional headwind from currency of about $0.05, which we are absorbing in our current outlook of $8.60-$8.80. That concludes our prepared remarks for the call.

Julie, would you please give the instructions, and we can start the Q&A?

Julie Winter (VP of Investor Relations and Corporate Communications)

Thank you, Mike and Dan, for your comments. Jamie, can you please give the instructions for Q&A, and we can get started?

Operator (participant)

Ladies and gentlemen, we'll now begin the question-and-answer session. To ask a question, you may press star and then one on your touchtone telephones. If you are using a speakerphone, we do ask you please pick up your handset prior to pressing the keys to ensure the best sound quality. To withdraw your questions, you may press star and two. Once again, that is star and then one to ask a question. We'll pause momentarily to assemble the roster. Our first question today comes from Jason Jacob from Stephens. Please go ahead with your question.

Jason Bednar (Senior Research Analyst)

Hey, good morning. Thanks for taking the questions. Maybe Dan or Mike, following up on kind of the last comments in the 2024 outlook, it seems like some of the year is playing out as expected, and appreciate the comps, but it also seems like healthcare going better than expected. Can you just talk about the other three segments and where things have changed the most? I think reading the tea leaves, Dan, maybe it seems like Life Sciences is the biggest delta since the beginning of the year, but just curious kind of how those other three segments are playing out this year versus original expectations.

Dan Carestio (President and CEO)

Yeah, I mean, I think we still expect to deliver a good year in Life Sciences. It's just there's still some continued destocking going on in the space, and you see this across, you know, everybody that's reported, you know, that sells either tools or disposables into the biopharma and pharma industries in general. You know, it's been announced in the last month or so that, you know, Pfizer is doing a $3.5 billion cut, and, you know, some other pharma companies are sort of following suit. So generally speaking, when we see that start to happen, there'll be a short-term pullback in the industry.

But the long-term outlook for, you know, for biopharma and aseptic manufacturing, which is really our sweet space, is, is really positive, and we have a great portfolio and expect to do well. In terms of, you know, in terms of the AST business, you know, as I mentioned, we've seen a positive trend in the U.S. You know, I think the procedures have crossed over with sort of the excess inventory that was out there in the past quarter, and we're seeing very positive growth from our medtech customers. In terms of Europe, it's taken a bit longer for that to happen. You know, there's been a lot of strikes, and there's been a lot of labor shortages in Europe, and just have not mobilized, you know, healthcare delivery in many places the way the U.S. has to date.

Eventually, that will abate, and even if it doesn't, eventually they're going to burn down the inventories and excess that they have sitting around. And I would have expected that around the time that we saw it in the U.S. I think as I've mentioned in previous calls, we expect it sometime in the fall time period. That's still the case. That could burn into the winter, I guess. But generally speaking, it's a matter of weeks or a few months, not quarters at this point. And then I think we've covered bioprocessing at length. Last year, Q2 was our high point. And then we started seeing it slowing in Q3 and ultimately sort of bottomed out by Q1 of our fiscal year, you know, give or take.

So the comps get easier for us in the second half for that, in terms of our performance, especially as we get into Q4 and then next fiscal year.

Jason Bednar (Senior Research Analyst)

Got it. Thanks for all that. Just, I guess my follow-up, just on backlog, both healthcare and life sciences down sequentially, is it fair to say healthcare is more about kind of execution and you catching up on lead times and maybe life sciences a little bit at the macro or anything else you'd share on that?

Dan Carestio (President and CEO)

Yeah, no, I would, I would say both are just getting products out the door. We had a lot of stuff that was supposed to move out in the prior quarter in life sciences, in particular, that, that slid till the end of the quarter and didn't get recognized till this quarter. So that's just purely a timing issue, and the orders remain pretty strong, and we've just been able to get a lot more stuff out of our factories, as we bring our lead times down pretty significantly. So we just had a great delivery quarter of capital in general, cross those businesses.

Jason Bednar (Senior Research Analyst)

Got it. Thanks for taking the questions.

Dan Carestio (President and CEO)

Yep, sure thing.

Operator (participant)

Our next question comes from Dave Turkaly from JMP Securities. Please go ahead with your question.

Dave Turkaly (Equity Research Analyst)

Hey, good morning. I just wanted to ask one follow-up on the AST side. It seems like we have some companies that are saying, you know, demand is super high. They're actually, like, experiencing bottlenecks to get devices sterilized. And you mentioned the timing of projects for AST, and I'm just curious, is there a shift going on, you know, between some of the modalities there? What exactly the medtech customer inventory that you're highlighting are you seeing?

Dan Carestio (President and CEO)

Well, like I said, we have seen demand come back really strong in the U.S. market in the past quarter, back to what I would consider sort of normalized growth rates, versus what we saw for the past two or three quarters. It's taken a bit longer for that recovery to happen outside of the U.S. You know, the plants are busy in North America, you know, and they're not as busy. I guess is what I would say, outside of, outside of the U.S. We expect that to change in the next quarter or so.

Michael Tokich (SVP and CFO)

Dave, the shortages, I think, have been more tied to EO sterilization.

Dan Carestio (President and CEO)

Yeah, very.

Michael Tokich (SVP and CFO)

Where our softness has been on the radiation side.

Dan Carestio (President and CEO)

Yeah.

Dave Turkaly (Equity Research Analyst)

No, that makes sense. And then maybe just to follow up for Julie or the team, you know, that master file, the pilot program. I'm just curious as to, you know, what you think that means for you. Obviously, it's, I think you said it's, you know, STERIS is first, but I don't know how to sort of analyze that or what you think that'll mean for you moving forward.

Dan Carestio (President and CEO)

Yeah. So Dave, so what it does is it really gives our customers the ability to significantly improve and build much more resilient supply chains. Specifically, it allows them to switch between different modes of sterilization, whether that's EO to X-ray, or gamma to X-ray, or even E-beam to gamma, or even to switch within our network of either our facilities or technologies without having to do a massive refile from a regulatory perspective. So products that are under 510(k) would not have to do a refile. Effectively, they would enter under our master file program, and then when they had their next normal sort of course of audits from the agency, they would check their records just to make sure everything was in place.

But it lowers a significant regulatory hurdle, I would say, that allows customers to build in much more resiliency and also switch between technologies.

Dave Turkaly (Equity Research Analyst)

Great. Thank you.

Dan Carestio (President and CEO)

Sure thing.

Operator (participant)

Our next question comes from Michael Polark from Wolfe Research. Please go ahead with your question.

Mike Polark (Senior Equity Research Analyst)

Hey, good morning. AST question for the back half. It obviously, the segment has the Mevex in it, and you break it out, so that's helpful. Not a lot of Mevex in the front half. Can you help level set how much Mevex you expect in the back half?

Dan Carestio (President and CEO)

In the second half, it'll be less than $15 million of total revenue, the first half, which was about $3 million. So again, not material, but unfortunately, year-over-year, the percentages are large, but the dollars are not.

Mike Polark (Senior Equity Research Analyst)

Yep, understood. No, it's helpful. And then on the AST services phasing, look, I hear all the destocking comments, and it sounds like light at end of tunnel, especially in U.S. devices, and bioprocessing, worst of it annualized in now. I'm looking at AST services in the front half, up 5% year-on-year. What's kind of a good either sequential growth rate or year-on-year growth rate to plan for in the back half?

Dan Carestio (President and CEO)

Yeah, in the second half, like, we expect double-digit, low double-digit growth rates getting back to more normalized.

Mike Polark (Senior Equity Research Analyst)

In the AST services line?

Dan Carestio (President and CEO)

The AST services line, exactly.

Mike Polark (Senior Equity Research Analyst)

Okay. Helpful. Appreciate that. And then the follow-up topic, equipment, healthcare, you know, it's not a metric you report, but we can do our own math. I calculate a book to bill, if you will, for you, for healthcare equipment. It was like 1.0 last quarter. It was sub 0.9 this quarter. But my question is on, like, the fresh order environment, and I want to set it up this way. Like, you have a big backlog. You have been working real hard to convert the backlog, and we're seeing conversion rates tick up, and that's pretty clear. I wonder about, like, your willingness to refill the backlog as fast.

Like, is there an element where you just, you know, do you need to bid for new business as much in the moment right now as you otherwise would because of the backlog, and that's a dynamic? So I'm curious there, and then just broadly on hospital capital spending, if you will, as we move into calendar 2024. Like, similar, seeing stresses and strains, no impact, and any thoughts on this would be great. Thanks.

Dan Carestio (President and CEO)

Yeah, just a couple-- That's a lot. Just a couple comments, and I would say is, you know, our orders remain strong, and, I mean, there's so much activity out in the field in terms of our portfolio right now. And you know, one of the positive signs I saw was the significant increase in the replacement business in the last quarter or so, versus the prior few periods. And that tells me that, A, our customers have confidence we can, in our field, also has confidence we can deliver in a relatively short period of time with normal lead times. You know, and B, they're willing to spend money on a lot of pent-up maintenance CapEx that our hospital systems have.

You know, I've talked about this before, and that is that although the healthcare providers are not necessarily killing it financially right now, they definitely are on a path to profitability, and many of them are in a good cash flow situation, whereas there was a lot more concern a year ago. The reality of it is, as well, is that our capital equipment is not. They're not luxury products. These are capacity enablers. You know, you can't do procedures without lights and tables. You can't do procedures without adequate capacity in the sterile processing department. And that's really what we do. It's not all that sexy, but it's a requirement.

Mike Polark (Senior Equity Research Analyst)

Thank you.

Operator (participant)

Our next question comes from Mike Matson from Needham and Company. Please go ahead with your question.

Mike Matson (Senior Equity Research Analyst)

Yeah, thanks. I guess I'll start with the dental business. You know, it was down again, and it looks like you're starting to lap some of the declines that you've been seeing. So, you know, is that- I guess, just what's the outlook there? Does it just really boil down to kind of the economic headwinds or something else maybe?

Dan Carestio (President and CEO)

Yeah, I mean, short term, we expect it to be about flat this fiscal year. And we would attribute that entirely to the economic, you know, downturn and the ability of people to spend cash right now on, on, on elective-type, dental-type procedures. And it's just generally impacting the entire industry, and others have spoken up on that topic prior to us, I'm sure, in the last couple weeks. You know, long term, we think it's a solid mid-single-digit grower. But some of these, some of these challenges facing, discretionary spending, you know, in particular in the U.S. economy, have got to get sorted out, in order for it to get back to those type numbers.

Mike Matson (Senior Equity Research Analyst)

Yeah, okay. And then, you know, it does look like you're obviously working down the backlog in the healthcare business, but, and, you know, I wanted to ask about just the hospital staffing with regard to the, you know, getting the equipment installed. I know that that's been an issue in the past, at least with some companies. Is, you know, have you seen that, you know, improving? Is that still a constraint on the, you know, ability to, you know, book the revenue there?

Dan Carestio (President and CEO)

No, we've seen that. I mean, there's more coordination today than there used to be, maybe, in terms of getting stuff received and at the docks and, you know, getting shipments married up so we can do install. But, you know, keep in mind, we've got well over 1,000 techs in the U.S. that do this work for us, you know, that are full-time STERIS employees, that are ready to go to help shepherd the process to get our stuff into the doors and also get it installed properly.

Mike Matson (Senior Equity Research Analyst)

Okay, got it. And then, I know you may have addressed this in the prepared remarks, so I got on the call a little late. So I just wanted to ask about the gross margin. It did look like it was down a little bit sequentially. And, you know, you had a nice improvement, I guess, last quarter sequentially from the Q4. But, you know, just any kind of commentary there would be helpful.

Dan Carestio (President and CEO)

Yeah, Mike, we had mentioned in the prepared remarks that, you know, even though margin, gross margin was down 50 basis points, we did have favorable price, but unfortunately, that was more than offset by lower productivity and continued material and labor inflation. So, you know, the productivity as we are moving stuff through the facility, we are not as efficient as we typically would be. So that negative productivity is hurting us in the short run.

Mike Matson (Senior Equity Research Analyst)

Yeah, got it. Thank you.

Julie Winter (VP of Investor Relations and Corporate Communications)

AST volumes declines sequentially don't help margin either.

Mike Matson (Senior Equity Research Analyst)

Yeah. Okay, thank you.

Operator (participant)

Once again, if you would like to ask a question, please press Star and One. Our next question comes from Jason Bednar from Piper Sandler. Please go ahead with your question.

Jason Bednar (Senior Research Analyst)

Hey, good morning. Thanks for taking the questions here. I want to start on, I think, the topic of the day here with AST, but maybe first on the CapEx side with AST. Just the decision to postpone some of those projects, that's influencing the CapEx outlook for the year. Appreciate you wanting to protect free cash flow, but is there a risk at all here that you're foregoing future growth in AST, just in not adding capacity? And should we be thinking about this CapEx spend shifting out of fiscal 2024 into 2025, and just next year being an above normal year of CapEx spend?

Dan Carestio (President and CEO)

Yeah, Jason, this is Dan. Thanks. Thank you for the question. Just to be very clear, we're not delaying these shipments. They were delayed just by natural building and current environment of getting things installed and everything else, and permitting processes and everything else. So it's we have not intentionally slowed those in any way. They've just naturally slowed. And yes, the answer is we would expect those now to be would bleed over into next fiscal year from a CapEx perspective. We haven't pulled any projects specifically. Yeah.

Jason Bednar (Senior Research Analyst)

Okay, Dan, you're talking about the CapEx spend, not the equipment that you're recognizing as revenue, just to be clear?

Dan Carestio (President and CEO)

Correct. Yes, I'm talking about CapEx spend.

Jason Bednar (Senior Research Analyst)

Okay. Okay, so it was, like, $65 million that shift, that, of spend that's shifting out of this year into next year?

Dan Carestio (President and CEO)

Yeah, the bulk of that is AST. It's not 100% AST, but the bulk of that $65 million is directly related to the AST segment.

Jason Bednar (Senior Research Analyst)

Got it. Okay. All right. Thank you. And then, we've had some questions here on backlog. It's down $100 million from peak levels. I know we were running well above normal for a long period of time. What do you see as the baseline? Where do you think backlog settles in a normal environment? You know, how much more backlog work down do you think we need to see before we're kind of at that, again, that normal level?

Dan Carestio (President and CEO)

We think normal is somewhere around 350, but we're happy to keep it higher if we keep pulling in orders. It was artificially high in the past because of our ability to manufacture and deliver, you know, and as we've sort of solved those issues from a supply chain perspective, you know, it's now really coming down at an accelerated pace.

Jason Bednar (Senior Research Analyst)

Got it.

Dan Carestio (President and CEO)

Although I would say that our lead times continue to be longer than we would like them to be. Yes.

Jason Bednar (Senior Research Analyst)

Okay. All right. Thanks. Then last question from me. I don't think I heard it, but yeah, if I did, I apologize. Are you able to bifurcate what you're seeing with your U.S. AST services business and contrast that against what you're seeing in Europe? You know, how much of a growth rate delta are you seeing across those two markets? It seems like the opportunity for improvement here is more dependent on the European market improving. So just wondering what kind of visibility you have on procedures in that geography recovering, and if you're seeing anything or hearing anything from your partners that would be an encouraging leading indicator.

Dan Carestio (President and CEO)

We do, we do look at it. We have a lot of data points, obviously, being in the hospitals and also dealing with directly with all of our customers and their insights on what's going on in the market. And there's a lot of public information from NHS and, you know, the other public health commissions in Europe. You know, what I would say is, it's got to get better, and even if the procedure rates don't improve, at some point, the inventory burn down crosses over, and we get back to normal stocking from our customer perspective. And, you know, everybody got really bloated on inventory over the last couple of years, and everybody now is trying to bring it down.

We've heard some customers say as much as 40% or 50%, and that takes considerable time. Like I said, we've crossed over that line in the US, and we believe that we'll get to that point in the coming weeks or months, definitely not quarters, I would say, you know, relative to the European destocking as it relates to medtech. And the other driver we talked about is, as we get into the back half of the year, the comps on bioprocessing, the single-use disposables, become a little easier against us. That's been a real headwind for the first two quarters of the year.

Jason Bednar (Senior Research Analyst)

Okay. All right. Thank you.

Operator (participant)

Ladies and gentlemen, at this point, in showing no additional questions, I'd like to turn the floor back over to the management team for any closing remarks.

Julie Winter (VP of Investor Relations and Corporate Communications)

Thank you, everybody, for taking the time to join us. I know you have a busy week. We do look forward to seeing many of you out on the road, over the next few weeks at several conferences.

Operator (participant)

Ladies and gentlemen, with that, we'll conclude today's conference call and presentation. Thank you for joining. You may now disconnect your line.